Ok. I think it’s important to note the article linked by Chet was paid for by CytoDyn. Here is medicalnews1 pricing
https://mn1.org/pricing
CytoDyn has several of these arrangements, clearly promoting the stock is important to their business model.
Regarding cancer, note all the excitement is over a few early results, which Culper covers well in their report. Here is the competition :
https://www.mrknewsroom.com/news-release/oncology/mercks-keytruda-pembrolizumab-combination-chemotherapy-met-primary-endpoint-pr Note this was success for mTBC, with 800+ patient enrollment. Also note the 1000+ ongoing clinical trial for Keytruda, vs CytoDyn’s single trial. The statement in the article that cancer treatment is changing in 30 day is 100% ridiculous. While I don’t think CytoDyn will sell any product at all in 2020, there is virtually zero chance they will commercialize for cancer.
The Coronavirus indication is a complete non starter. A quick google anyone can see many realistic candidates being investigated/trialed, none are cytodyn’s option.
Viewing the CytoDyn video attached to this page, I noticed the CEO mentioned HIV was the top indication for the drug. He is right. I think the upside is detailed in the Culper report. I have some insight on the upcoming competition in this market.
Fire away with comments, questions, and criticism.